Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma.
Saved in:
| Title: | Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. |
|---|---|
| Authors: | Hasanov M; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA., Kiany S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Forget MA; Cell Therapy Manufacturing Center, Houston, TX, USA., Bassett R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Glitza IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lucci A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McQuade JL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel SP; Department of Medical Oncology, University of Colorado, Aurora, CO., Ross MI; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wong MK; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bernatchez C; Cell Therapy Manufacturing Center, Houston, TX, USA., Hwu P; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | Oncoimmunology [Oncoimmunology] 2025 Dec; Vol. 14 (1), pp. 2546402. Date of Electronic Publication: 2025 Aug 15. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
